Physician profile
Jaime E Estrada
NPI 1306917661
$5,203.19
in general payments reported to CMS, 2019-2025
36 companies · $813 in 2025
The $813 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $988 · 2021: $1,186 · 2022: $619 · 2023: $682 · 2024: $513 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000 · Education: $8.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.33 |
| Education | $8.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,193.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $754.54 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Corcept Therapeutics | $382.20 | 2021-2025 | Korlym |
| Lilly USA, LLC | $372.04 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $269.62 | 2020-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $204.86 | 2019-2021 | |
| Amgen INC. | $177.59 | 2019-2025 | Evenity, Repatha, Prolia |
| Xeris Pharmaceuticals, INC. | $166.01 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $147.66 | 2020-2021 | |
| Boston Scientific Corporation | $118.21 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.27 | 2022-2025 | |
| Amarin Pharma, INC. | $115.82 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $109.46 | 2021-2024 | Linzess |
| Janssen Pharmaceuticals, INC | $103.23 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $95.12 | 2019-2021 | |
| Abbvie INC. | $70.91 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.81 | 2021-2025 | Jardiance |
| Globus Medical, INC. | $65.36 | 2025 | Senza |
| Novartis Pharmaceuticals Corporation | $62.72 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $62.12 | 2025 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.43 | 2020-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $46.85 | 2020-2021 | |
| Abbott Laboratories | $40.72 | 2022-2023 | Freestyle Libre 3 |
| Stryker Corporation | $40.18 | 2025 | Prostep Mica |
| Merck Sharp & Dohme LLC | $37.62 | 2021 | |
| Cequr Corporation | $30.84 | 2025 | Cequr Simplicity |
| Nevro Corp. | $30.19 | 2024 | Senza |
| Recordati_rare_diseases_inc. | $26.37 | 2025 | Isturisa |
| Shield Therapeutics INC | $24.27 | 2025 | |
| Phathom Pharmaceuticals, INC. | $23.29 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $21.72 | 2019 | |
| Medtronic Minimed, INC. | $19.31 | 2020 | |
| Hologic Sales and Service, LLC | $19.27 | 2022 | |
| Dexcom, INC. | $16.00 | 2023 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $15.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Estrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.